

## Disopyramide – Shortage/Out of stock

*This information has been produced in liaison with the cardiology clinical pharmacist.*

### Shortage information

A shortage of disopyramide 100mg immediate release capsules and 250mg modified release (MR) tablets has been reported via local intelligence. This is based on limited company information received from Neon Healthcare on 25<sup>th</sup> July 2023.

The 100mg capsules are expected to be available mid-end august. There is no resupply date for the 250mg MR tablets.

### Prescribing in NHS Grampian

28 patients have been identified as being prescribed the 100mg capsules.

9 patients have been identified as being prescribed the 250mg Modified Release tablets.

### Stock information & availability

- Unlicensed special supplies of 100mg capsules and suspension may be available from various suppliers including Ethigen, Target and Aclardian.

### Formulary status

Disopyramide is included in the [Grampian Area Formulary](#) for supraventricular and ventricular arrhythmias. Treatment may be initiated in Primary Care on the recommendation of a consultant/specialist.

### Actions for primary care

Efforts should be made to identify levels of patient personal stock and any available stock/ability to order licensed products within local community pharmacies.

- For patients currently prescribed 250mg Modified Release tablets – if these cannot be obtained. Consider the total daily dose the patient requires utilising the unlicensed 100mg immediate release capsules.  
Maintain the total daily dose but give in divided doses. For example 250mg MR tablets twice daily – could be changed to 200mg morning and night and 100mg at lunchtime.  
Ensure patients are made aware of any change to prescribing with particular emphasis on changed doses and timing of doses.
- For patients currently prescribed 100mg immediate release capsules unlicensed supplies may require to be obtained
- The NHS Grampian Specials Authorisation process should be followed prior to any unlicensed supplies being ordered. The prescriber must agree to the need for unlicensed special and the patient should be made aware.

### Data information

- *Data provided is ePrescribed (April-July 23) (run 26/7/23)*
- *The data provides prescribing information. It does not confirm that the prescription has been dispensed by community pharmacy or collected by the patient.*
- *The data only captures electronic prescribing information – any handwritten prescriptions will not be included*